YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==Q10 COENZYME== 18 AUTHOR Greenberg S AUTHOR Frishman WH TITLE Co-Enzyme Q10: new drug for cardiovascular disease SOURCE J. Clin. Pharmacol.; VOL 30 ISS Jul 1990, P596-608, (REF 133) ABSTRACT IPA COPYRIGHT: ASHP A review of the chemistry, biological actions, mechanisms of action, oral pharmacokinetics, adverse effects, and clinical experiences of ubidecarenone (coenzyme Q10) in angina pectoris, congestive heart failure, hypertension, doxorubicin (adriamycin) induced cardiotoxicity, myocardial protection during open heart surgery, and arrhythmias are presented. 23 AUTHOR Miyazaki Y AUTHOR Nagai S AUTHOR Hattori M AUTHOR Ogawa K AUTHOR Ozawa T AUTHOR et al TITLE Effect of coenzyme Q10 against the attack of phospholipase to myocardial membrane SOURCE Arzneim. Forsch.; VOL 36 ISS 2 1986, P187-189, (REF 16) ABSTRACT IPA COPYRIGHT: ASHP A study designed to clarify the biochemical and electrophysiological influences of phospholipase (PLase) A2 and PLase C on canine myocardial membrane and to investigate the effect of coenzyme Q10 (ubidecarenone; I) against the action of these enzymes is reported. Premedication with I significantly prevented all biochemical and electrophysiologic changes induced by the action of PLases suggesting that I exerts a protective effect on myocardial membrane against the attack of PLases. 25 AUTHOR Perna A AUTHOR Patane E AUTHOR Brancato V TITLE Use of ubidecarenone in the therapy of cardiac patients with bronchopneumonia SOURCE Boll. Chim. Farm.; VOL 125 ISS Mar 1986, P46S-52S, (REF 31) ABSTRACT IPA COPYRIGHT: ASHP Thirty-one cardiac patients suffering from specific pulmonary diseases were treated with ubidecarenone (coenzyme Q10; I) and basic therapy usually used in such cases. Results after using I were positive in terms of global cardiocirculatory functions. 26 AUTHOR Ghiringhelli G TITLE Ubidecarenone therapy of some cardiopathies with and without decompensation: comparison with standard therapy SOURCE Boll. Chim. Farm.; VOL 125 ISS Mar 1986, P28S-33S, (REF 51) ABSTRACT IPA COPYRIGHT: ASHP Patients suffering from various cardiopathies were administered standard cardiac agents and compared with another group that received standard therapy in addition to ubidecarenone (coenzyme Q10; I). Better therapeutic results were obtained in patients receiving I plus standard therapy. 35 AUTHOR Folkers K AUTHOR Wolaniuk A TITLE Research on coenzyme Q10 in clinical medicine and in immunomodulation SOURCE Drugs Exp. Clin. Res.; VOL 11 ISS 8 1985, P539-545, (REF 4) ABSTRACT IPA COPYRIGHT: ASHP The use of ubidecarenone (coenzyme Q10; ubiquinone-10) as an immunomodulating agent in the therapy of resistant myocardial failure is discussed. Various models were used to evaluate parameters of the immune system, including phagocytic rate, circulating antibody level, neoplasia, viral and parasitic infections. The effect was enhanced when the drug was used with other drugs. 44 AUTHOR Gini M AUTHOR Schiavi M AUTHOR Mazzola C TITLE Use of ubidecarenone (coenzyme Q10) in the treatment of pulmonary cardiopathy SOURCE Boll. Chim. Farm.; VOL 124 ISS Apr 1985, P21S-28S, (REF 45) ABSTRACT IPA COPYRIGHT: ASHP A daily dose of 60 mg of ubidecarenone (coenzyme Q10; I) was administered to 27 patients with chronic bronchopulmonary diseases or pulmonary cardiopathy to evaluate its therapeutic effectiveness. A statistically significant and persistent improvement of certain indices of myocardium function was observed after one month of therapy. During this time there was also a good restoration of hemodynamic balance and a normalization of the systolic output and the related indexes.